RARA CRAFT DATABASE for FDA Medical Devices

FDA medical device news and insights

News articles that explain new FDA clearances and approvals, guidance, AI devices and premarket pathways in plain terms — for product development and regulatory teams.

The 3 newest articles are free to read in full. Members can read every article.

日本語の記事
  1. FDA UpdatesFDA Publishes a PCCP Page With a List of 240 Devices; 20 Records Not on the List Have PCCP Review Language in Their LettersOn October 20, 2026, FDA published a page on predetermined change control plans (PCCPs) with a list of 240 devices authorized with a PCCP, along with hypothetical case examples for AI devices. Fifty-six of the 240 are PMA supplements; of the 46 whose approval statements say what the PCCP covers, about four in five plan manufacturing, supplier or facility changes. One hypothetical example is an AI that goes from retraining to deployment without human decision-making. Checked against RA Craft Database records, 20 510(k)s are absent from the list and read No in the PCCP field on FDA's record pages, yet their clearance letters say a PCCP was reviewed and cleared. For 16, other text confirms the plan's title or content; for four, only the letter's standard paragraph does.
  2. FDA UpdatesCDRH's FY 2027 Guidance Plan: PCCP Stays on the A-List and AI Software Moves Up From the B-ListFDA's Center for Devices and Radiological Health (CDRH) has published its guidance plan for fiscal year 2027 (October 2026 to September 2027). The A-list, which prioritizes publication during the year, has eight items. Finalizing the PCCP guidance for medical devices in general is on it for the second year running, and finalizing the AI-enabled device software functions guidance has moved up from the B-list. A planned draft on generative AI-enabled conversational devices for mental disorders is new. We set the FY 2027 items against last year's plan and list the items that were on last year's plan but are not on this one. Comments on the plan are open until November 30.
  3. Data InsightsFrom Blood Pressure Monitors to Pocket Ultrasound: Wireless Medical Devices in 132 FDA Submission Records, January 2025 to September 2026Among FDA decisions from January 2025 through September 2026, RA Craft Database identified 132 submission records whose public documents confirm wireless communication for a device that is worn, carried or used at home. We sort them by field, from wearable ECG and sleep testing to home blood pressure monitors, home therapy devices and handheld ultrasound with wireless probes, show what connects to what, and count the records whose public documents mention wireless testing or cybersecurity.
  4. Monthly FDA ApprovalsMembersDoes Every Breakpoint Revision or New Connection Need a 510(k)? The Conditions September 2026's PCCPs Set in AdvanceA PCCP is not only for retraining an AI model. Among the eighteen FDA decisions with a PCCP in September 2026, several plan to re-evaluate antimicrobial breakpoints, add operating systems and data connections to insulin-dosing apps, add compatible insulins to an insulin pump, move a catheter's manufacturing site or extend a test to more laboratories. We trace them back through the same companies' earlier filings and FDA's review documents. What the 510(k) Summaries leave out, FDA's Decision Summaries and the approval statements on PMA records often supply.
  5. Monthly FDA ApprovalsMembersWhat Is a Retrained AI Compared With Before It Goes Live? Seven PCCPs from September 2026, One Retraining DailySeven devices cleared with a PCCP in September 2026 could be confirmed as AI/ML. We read each 510(k) Summary against what FDA's AI PCCP guidance asks for, a description of modifications, a modification protocol, an impact assessment and labeling. What a retrained model is compared with, how much of the acceptance criteria is public, and how an update is adopted vary from one Summary to the next. Set beside other plans from the same companies, the differences in public documents are kept apart from differences in the plans themselves.
  6. Monthly FDA ApprovalsMembersFrom a Manufacturing Site to Test Breakpoints: What September 2026's Eighteen PCCPs Plan to ChangeEighteen FDA decisions in September 2026 came with a Predetermined Change Control Plan. We checked each one in whichever of the 510(k) Summary, the clearance letter, FDA's Decision Summary and the approval statement on FDA's PMA record are public, and kept three things apart, whether the device uses AI, what the plan covers, and how far the public documents let us confirm it. Besides retraining an AI model, the plans cover re-evaluating antimicrobial breakpoints, adding operating systems, data connections and compatible insulins, moving a manufacturing site and extending use to more laboratories.
  7. Device SpotlightMembersOtoCompanion Detects Middle Ear Fluid in Otoscopic Images and Is Cleared on 181 Ears Checked at MyringotomyOtoCompanion (Ironsides Medical) reads still images of a child's ear and returns "Fluid Present" or "Dry." It received 510(k) clearance on September 21, 2026. The predicate is Tyto Care's eardrum bulging detector, granted through De Novo six months earlier, which looks for a different finding, takes a different input and is sold over the counter. We read the validation against surgical findings and the two records now in product code SHL.
  8. Device SpotlightMembersMedical AI's ECG Algorithm AiTiALVSD, Trained in Korea and Validated on 22,101 U.S. Patients, Is Cleared Under QYEAiTiALVSD, from Seoul-based Medical AI Co., Ltd., reads a 12-lead ECG and returns High or Low for the likelihood of a left ventricular ejection fraction of 40% or less. It received 510(k) clearance on September 30, 2026. The model was trained on 400,000 Korean ECGs and validated on 22,101 U.S. patients, with 83.7% sensitivity and 81.0% specificity. We compare it with the Anumana predicate and the six devices now in product code QYE.
  9. Device SpotlightMembersBiolinq Shine, the Glucose Monitor That Shows a Color Instead of a Number, Goes OTC a Year After Its De NovoBiolinq Shine, a forearm-worn glucose sensor whose LED shows blue, yellow or red for the glucose range, received 510(k) clearance for over-the-counter use on September 18, 2026. The predicate is the company's own De Novo, granted as a prescription device in September 2025. We look at how a monitor with no numeric readout was evaluated and what changed for the OTC version.
  10. Device SpotlightMembersHappy Health's Ring-Based Blood Pressure Monitor Is Cleared Without Cuff CalibrationHappy Health's ring-based blood pressure monitor received 510(k) clearance on September 3, 2026. It reports systolic and diastolic pressure in mmHg with no cuff calibration and no demographic inputs. We read the 510(k) Summary alongside the draft guidance on cuffless blood pressure devices that FDA issued in January.
  11. Device SpotlightMembersEpic's Deterioration Score Ran in Hospitals for Years. Now It Has a 510(k).The new version of Epic's Deterioration Index, a risk score that has run inside the EHR for years, was cleared in September 2026. The predicate is a product another company cleared two years earlier for the same job. The giant came through the door second.
  12. Monthly FDA ApprovalsMembersFDA Guidance and Notices, September 2026: Draft Guidance on Robotically-Assisted Surgical Devices and a PMA Electronic Submission TemplateFDA's device-related guidance, rules and notices from September 2026, with a short note on each: draft guidance on robotically-assisted surgical devices and a PMA electronic submission template, final 510(k) guidance for two dental device types, and new work on rare disease devices.
  13. Data InsightsHow Many 510(k)s Does FDA Clear a Year? 2021–2025 Counts and the Top 20 Product CodesAbout 3,000 to 3,300 clearances a year, and a quarter of them land in just 20 product codes. Number one is the examination glove and number two the surgical mask, but both were concentrated in 2021–2022; in 2025 the busiest of the twenty was automated radiological image processing software. Five years of counts, the top 20 codes and how they moved, and what a code's volume means for your predicate search.
  14. Site News & How-toA New FDA Device Database Is Born: Meet RA Craft DatabaseSearch FDA 510(k), De Novo and PMA records in English or Japanese, star the ones that matter, and read their Indications for Use side by side. A new FDA device database, RA Craft Database, is now open. It started with the stop-and-wait feel of working in FDA's database. Here is what it does, where it came from, and what you should know before you rely on it.
  15. AI & Digital HealthHow Many AI-Enabled Devices Has FDA Authorized? FDA's Figure and Our CountFDA says it has authorized more than 1,600 AI-enabled medical devices, and also that its list is not comprehensive. We set FDA's figure beside our own count of records confirmed as AI/ML-enabled, explain how the two are counted, and break the records down by year, pathway and review panel.
  16. Device SpotlightDevice Spotlight — DeepView AI System (DEN250028): Reading the De Novo Record for a Burn-Assessment AIOn May 21, 2026, FDA granted De Novo authorization to Spectral MD's DeepView AI System, software that highlights deep burn tissue in images. We read the record in order (classification name and regulation, the verbatim Indications for Use, the seven special controls) and look at what it means for devices that may follow under product code SHY.
  17. AI & Digital HealthWhat Is a PCCP? How FDA Lets AI Devices Change Without a New SubmissionA Predetermined Change Control Plan (PCCP) lets a manufacturer get future changes to an AI-enabled device reviewed up front, so updates that stay inside the authorized plan need no new marketing submission. Here is what goes into one, which submissions can carry it, what "within the plan" means, and how to read PCCP language in FDA's public records.
  18. Regulatory BasicsReading an FDA Product Code — and Using It to Find Your PredicateA predicate search goes further when it starts from an FDA product code rather than a product name. What a code tells you, how De Novo creates new ones, how to narrow the candidates under one code, and what to do when no code fits, using real records under QNP and DEN250028 (SHY).
  19. Regulatory Basics510(k), De Novo, or PMA? Telling Them Apart with Real FDA RecordsA marketing draft says "FDA-approved" and the footnote shows a K number. At a high level, the three premarket pathways can be told apart by what the device is compared against. We open one real record from each, SKOUT system (510(k)), DeepView AI System (De Novo) and Claire OCT System (PMA), and read what each public document contains.
  20. Monthly FDA ApprovalsMembersFDA Guidance and Notices, August 2026: Revised Human Factors Guidance and a Discussion Paper on Generative AI DevicesFDA's device-related guidance, rules and notices from August 2026, each with a short note. Highlights include the revised human factors and usability engineering guidance, a discussion paper on generative AI-enabled devices and a proposed list of accessories suitable for class I.
  21. Monthly FDA ApprovalsFDA Device Decisions, August 2026: A Blood-Drawing Robot, a Glucose-Ketone CGM and Five New De Novo ClassificationsWhat FDA cleared, granted and approved in August 2026, from RA Craft Database's tally and FDA's public records. The five De Novo grants, including an autonomous phlebotomy robot and a combined glucose-ketone sensor, each created a new classification; we read their indications and special controls, then the month's three original PMAs.
  22. Monthly FDA ApprovalsMembersFDA Guidance and Notices, July 2026: MDUFA VI Proposals and FY2027 Device User FeesFDA's device-related guidance, rules and notices from July 2026, briefly explained. The month brought the proposed MDUFA VI package for comment, fiscal year 2027 user fees and final guidance on 510(k) submissions for hemodialysis blood tubing sets.
  23. Monthly FDA ApprovalsFDA Device Decisions, July 2026: A Surgical Robot, Five De Novo Grants and Four Original PMAsWhat FDA cleared, granted and approved in July 2026, tallied from records held in RA Craft Database. Counts by pathway against June and July 2025, the busiest product codes, all five De Novo grants and four original PMAs, and three devices worth a closer read.
  24. Monthly FDA ApprovalsMembersFDA Guidance and Notices, June 2026: Final Policy on Exempting Unclassified Devices From 510(k), and a Wave of Classification RulesFDA's device-related guidance, rules and notices from June 2026, with a short note on each. FDA updated its final policy on exempting certain unclassified devices from 510(k), and a long run of classification rules appeared.
  25. Monthly FDA ApprovalsFDA Device Decisions, June 2026: A Blood Test for Esophageal Varices, Six Original PMAs and One De Novo GrantWhat FDA cleared, granted and approved in June 2026, tallied from records held in RA Craft Database. Counts by pathway against May and June 2025, the busiest product codes, the month's De Novo grant and six original PMAs, and three devices worth a closer read.
  26. Monthly FDA ApprovalsMembersFDA Guidance and Notices, May 2026: Final Guidance on Human Factors Information and Patient-Matched Orthopedic GuidesA list of FDA's device-related guidance, rules and notices from May 2026, with a short note on each. Final guidance on human factors information in marketing submissions and on patient-matched guides for orthopedic implants came out this month.
  27. Monthly FDA ApprovalsFDA Device Decisions, May 2026: A Home Neurostimulator for PTSD, Four De Novo Grants and Five Original PMAsWhat FDA cleared, granted and approved in May 2026, tallied from records held in RA Craft Database. Counts by pathway against April and May 2025, the busiest product codes, all four De Novo grants and five original PMAs, and three devices worth a closer read.
  28. Monthly FDA ApprovalsMembersFDA Guidance and Notices, April 2026: The FDA-CMS RAPID Pathway and Device Classification RulesFDA's device-related announcements, guidance and rules from April 2026, with brief notes. The list covers the FDA-CMS RAPID pathway, the READI-Home innovation challenge, a draft on NIOSH-approved respirators and a set of device classification rules.
  29. Monthly FDA ApprovalsFDA Device Decisions, April 2026: MRI Software for Parkinsonian Syndromes, Three De Novo Grants and One Original PMAWhat FDA cleared, granted and approved in April 2026, tallied from records held in RA Craft Database. Counts by pathway against March and April 2025, the busiest product codes, all three De Novo grants and the month's original PMA, and three devices worth a closer read.
  30. Monthly FDA ApprovalsMembersFDA Guidance and Notices, March 2026: Final Guidance on Weight-Loss Devices and Patient Preference InformationFDA's device-related guidance, rules and safety communications from March 2026, briefly explained. Final guidance on weight-loss devices, pyrogen and endotoxins testing, and patient preference information is listed alongside a batch of withdrawn older guidance.
  31. Monthly FDA ApprovalsFDA Device Decisions, March 2026: An Anti-Choking Device, a Transcatheter Valve for Aortic Regurgitation and MoreWhat FDA cleared, granted and approved in March 2026, tallied from records held in RA Craft Database. Counts by pathway against February and March 2025, the busiest product codes, both De Novo grants and the month's original PMAs, and three devices worth a closer read.
  32. Monthly FDA ApprovalsMembersFDA Guidance and Notices, February 2026: A QMSR Inspection Program and Revised Cybersecurity GuidanceFDA's device-related guidance, rules and notices from February 2026, the month a QMSR-based inspection program began. Revised cybersecurity and software assurance guidance and proposed 510(k) exemptions for Class II devices are among the items, each with a short note.
  33. Monthly FDA ApprovalsFDA Device Decisions, February 2026: An AI That Predicts Delivery Dates, Two De Novo Grants and Five Original PMAsWhat FDA cleared, granted and approved in February 2026, tallied from records held in RA Craft Database. Counts by pathway against January and February 2025, the busiest product codes, both De Novo grants and all five original PMAs, and three devices worth a closer read.
  34. Monthly FDA ApprovalsMembersFDA Guidance and Notices, January 2026: Final Guidance on Clinical Decision Support Software and General WellnessFDA's device-related guidance and notices from January 2026, with a line or two on each. The month brought final guidance on clinical decision support software and on low-risk general wellness products, and a draft on cuffless blood pressure devices.
  35. Monthly FDA ApprovalsFDA Device Decisions, January 2026: A Liquid Embolic for Chronic Subdural Hematoma, Two De Novo Grants and Two Original PMAsWhat FDA cleared, granted and approved in January 2026, tallied from records held in RA Craft Database. Counts by pathway against December and January 2025, the busiest product codes, both De Novo grants and both original PMAs, and three devices worth a closer read.
  36. Monthly FDA ApprovalsFDA Guidance and Notices, December 2025: Final Guidance on Real-World Evidence for Devices and QMSR Technical AmendmentsA list of FDA's device-related guidance, rules and notices from December 2025, each with a brief note. Highlights are final guidance on real-world evidence for devices and on eCopy, QMSR technical amendments, and the TEMPO pilot for digital health devices.
  37. Monthly FDA ApprovalsFDA Device Decisions, December 2025: Transcatheter Mitral Valve Replacement, Home Neurostimulation for Depression and Ten Original PMAsWhat FDA cleared, granted and approved in December 2025, tallied from records held in RA Craft Database. Counts by pathway against November and December 2024, the busiest product codes, both De Novo grants and all ten original PMAs, and three devices worth a closer read.
  38. Monthly FDA ApprovalsFDA Guidance and Notices, November 2025: Final Guidance on Pre-RFDs and Draft ICH Q3E on Extractables and LeachablesFDA's device-related guidance, rules, notices and safety communications from November 2025, with brief notes. FDA finalized guidance on preparing a Pre-Request for Designation (Pre-RFD) and released the draft ICH Q3E guideline on extractables and leachables.
  39. Monthly FDA ApprovalsFDA Device Decisions, November 2025: Focused Ultrasound for Facet Joint Pain, Two De Novo Grants and Two Original PMAsWhat FDA cleared, granted and approved in November 2025, tallied from records held in RA Craft Database. Counts by pathway against October and November 2024, the busiest product codes, both De Novo grants and both original PMAs, and three devices worth a closer read.
  40. Monthly FDA ApprovalsFDA Guidance and Notices, October 2025: Draft Guidance on QMS Information in Premarket Reviews and a Warning on RF MicroneedlingFDA's device-related guidance and safety communications from October 2025, each with a brief note. FDA issued drafts on quality management system information for certain premarket reviews and on menstrual products, and warned about radiofrequency (RF) microneedling.
  41. Monthly FDA ApprovalsFDA Device Decisions, October 2025: Cryoablation for Low-Risk Breast Cancer, Home Fetal Ultrasound and Four De Novo GrantsWhat FDA cleared, granted and approved in October 2025, tallied from records held in RA Craft Database. Counts by pathway against September and October 2024, the busiest product codes, all four De Novo grants and the original PMA, and three devices worth a closer read.
  42. Monthly FDA ApprovalsFDA Guidance and Notices, September 2025: Final Computer Software Assurance Guidance and the LDT Rule VacaturFDA's device-related guidance, rules, advisory committee notices and safety communications from September 2025, each briefly explained. The main items are final guidance on computer software assurance for production and quality system software and a rule implementing the court's vacatur of the laboratory developed test (LDT) rule.
  43. Monthly FDA ApprovalsFDA Device Decisions, September 2025: Spectacle Lenses to Slow Myopia in Children, Three De Novo Grants and Four Original PMAsWhat FDA cleared, granted and approved in September 2025, tallied from records held in RA Craft Database. Counts by pathway against August and September 2024, the busiest product codes, all three De Novo grants and four original PMAs, and three devices worth a closer read.
  44. Monthly FDA ApprovalsFDA Guidance and Notices, August 2025: Revised PCCP Guidance for AI-Enabled Devices and a Batch of Classification RulesFDA's device-related guidance, rules and letters to health care providers from August 2025, with a short note on each. FDA revised its final guidance on Predetermined Change Control Plans (PCCPs) for AI-enabled devices, issued final guidance on animal studies for dental bone grafting materials, and published a batch of classification rules.
  45. Monthly FDA ApprovalsFDA Device Decisions, August 2025: Pulsed Field Ablation, Bilateral Hypoglossal Nerve Stimulation and Six Original PMAsWhat FDA cleared, granted and approved in August 2025, tallied from records held in RA Craft Database. Counts by pathway against July and August 2024, the busiest product codes, the De Novo grant and all six original PMAs, and three devices worth a closer read.
  46. Monthly FDA ApprovalsFDA Guidance and Notices, July 2025: FY2026 Device User Fees and Final Guidance on Small Business QualificationFDA's device-related guidance, notices and safety updates from July 2025, with a short note on each. The month brought the fiscal year 2026 device user fee rates and final guidance on qualifying as a small business.
  47. Monthly FDA ApprovalsFDA Device Decisions, July 2025: Vagus Nerve Stimulation for Rheumatoid Arthritis, Four Original PMAs and One De Novo GrantWhat FDA cleared, granted and approved in July 2025, tallied from records held in RA Craft Database. Counts by pathway against June and July 2024, the busiest product codes, the De Novo grant and all four original PMAs, and three devices worth a closer read.
  48. Monthly FDA ApprovalsFDA Guidance and Notices, June 2025: Cybersecurity Final Guidance and Draft Guidance on 510(k) Clearance TransfersFDA's device-related guidance, rules, notices and safety communications from June 2025, briefly annotated. Among them are final cybersecurity guidance, a draft on 510(k) clearance transfers and a call for comments on MDUFA reauthorization.
  49. Monthly FDA ApprovalsFDA Device Decisions, June 2025: A Bone Graft That Beat Autograft in Lumbar Fusion, Sutureless Nerve Repair and Three De Novo GrantsWhat FDA cleared, granted and approved in June 2025, tallied from records held in RA Craft Database. Counts by pathway against May and June 2024, the busiest product codes, all three De Novo grants and all three original PMAs, and three devices worth a closer read.
  50. Monthly FDA ApprovalsFDA Guidance and Notices, May 2025: Q-Submission Program Final Guidance and a Draft Electronic TemplateFDA's device-related guidance, rules and announcements from May 2025, with brief notes. The month brought final guidance on the Q-Submission Program and a draft electronic template for it, an expansion of unannounced foreign inspections and a batch of device classification rules.
  51. Monthly FDA ApprovalsFDA Device Decisions, May 2025: A Transcatheter Mitral Valve for Severe Annular Calcification, Five-Year Breast Cancer Risk Software and Four De Novo GrantsWhat FDA cleared, granted and approved in May 2025, tallied from records held in RA Craft Database. Counts by pathway against April and May 2024, the busiest product codes, all four De Novo grants and all three original PMAs, and three devices worth a closer read.
  52. Monthly FDA ApprovalsFDA Guidance and Notices, April 2025: False Positive Blood Lead Results and the STIC Annual CompilationThe two device-related documents FDA issued in April 2025, with notes: a safety communication on false positive blood lead results, and the Federal Register compilation of 2024 updates to the Susceptibility Test Interpretive Criteria (STIC).
  53. Monthly FDA ApprovalsFDA Device Decisions, April 2025: Leadless Left-Ventricular Pacing, Behavioral Therapy Software for Migraine, Four De Novo Grants and Three Original PMAsWhat FDA cleared, granted and approved in April 2025, tallied from records held in RA Craft Database. Counts by pathway against March and April 2024, the busiest product codes, all four De Novo grants and all three original PMAs, and three devices worth a closer read.
  54. Monthly FDA ApprovalsFDA Guidance and Notices, March 2025: Sex-Specific Data in Device Clinical Studies and a Recognized Standards UpdateFDA's device-related guidance, notices and other documents from March 2025, each with a short note. The main ones are final guidance on sex-specific data in device clinical studies and Recognition List 063; there was also a letter on hemodialysis bloodline shortages.
  55. Monthly FDA ApprovalsFDA Device Decisions, March 2025: An Over-the-Counter PCR Test for Sexually Transmitted Infections, an Endoscope Channel Cleaner and No Original PMAsWhat FDA cleared, granted and approved in March 2025, tallied from records held in RA Craft Database. Counts by pathway against February and March 2024, the busiest product codes, and both De Novo grants. There were no original PMA approvals in March.
  56. Monthly FDA ApprovalsFDA Guidance and Notices, February 2025: IRB Written Procedures and Smartphone Alerts for Diabetes DevicesThe two device-related documents FDA issued in February 2025, with a short note on each: a revised final guidance on IRB written procedures and a safety communication on smartphone alert settings for diabetes devices.
  57. Monthly FDA ApprovalsFDA Device Decisions, February 2025: A Hyaluronic Acid Filler, a Spine Sealant and No De Novo GrantsWhat FDA cleared, granted and approved in February 2025, tallied from records held in RA Craft Database. Counts by pathway against January and February 2024, the busiest product codes, and both original PMAs. There were no De Novo grants in February.
  58. Monthly FDA ApprovalsFDA Guidance and Notices, January 2025: Draft Guidance on AI-Enabled Device Lifecycle Management and Pulse OximetersFDA's device-related guidance, rules and safety communications from January 2025, each with a short note. They include draft guidance on AI-enabled device software lifecycle management and on pulse oximeters, and final guidance on PMA and HDE modular review.
  59. Monthly FDA ApprovalsFDA Device Decisions, January 2025: Kidney Function Measured Through the Skin, a Muscle-Fatigue Device for Athletes and Two Original PMAsWhat FDA cleared, granted and approved in January 2025, tallied from records held in RA Craft Database. Counts by pathway against December 2024 and January 2024, the busiest product codes, the De Novo grant and both original PMAs, and three devices worth a closer read.